957 filings
S-8
IMGN
Immunogen, Inc.
21 Dec 20
Registration of securities for employees
4:58pm
8-K
IMGN
Immunogen, Inc.
18 Dec 20
Entry into a Material Definitive Agreement
5:19pm
424B5
IMGN
Immunogen, Inc.
18 Dec 20
Prospectus supplement for primary offering
5:16pm
S-3ASR
IMGN
Immunogen, Inc.
18 Dec 20
Automatic shelf registration
4:45pm
8-K
IMGN
Immunogen, Inc.
18 Dec 20
Other Events
4:16pm
8-K
c55i 8g8w1
11 Dec 20
Other Events
4:40pm
8-K
1zxwvj
7 Dec 20
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
8:02am
8-K
uygki8sq8lp64c
6 Nov 20
ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results
6:53am
8-K
amfxk
26 Oct 20
Departure of Directors or Certain Officers
9:22am
8-K
mkd9s535 bc4b94
19 Oct 20
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
8:57am
8-K
9enpvi 86w
13 Oct 20
Other Events
8:11am
4
8snm0vy2qb
1 Oct 20
ImmunoGen / Mark Alan Goldberg ownership change
2:39pm
4
flntw
1 Oct 20
ImmunoGen / DEAN J MITCHELL ownership change
2:38pm
8-K
1rnvje lq6eqkvg
25 Sep 20
Entry into a Material Definitive Agreement
4:38pm
424B5
bud1ge5y bv0
25 Sep 20
Prospectus supplement for primary offering
4:23pm
8-K
0bmh3x
31 Jul 20
ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results
8:41am
8-K
6gmqu9rub0h
22 Jul 20
ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer
4:10pm
4
mzms48y9hdmf 8h
22 Jul 20
ImmunoGen / Susan ALTSCHULLER ownership change
3:44pm